---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-002078"
form_type: "8-K"
ticker: "AURX"
cik: "0001091596"
company_name: "Nuo Therapeutics, Inc."
filed_at: "2026-01-26T23:59:59+00:00"
generated_at: "2026-05-16T07:48:45.481280+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nuo Therapeutics secures up to $1.6M loan with 10%-12% PIK interest paid in warrants; insider participation

## Summary
- Loan agreement for $1.0M initial + $600K second tranche (Sept 30, 2026); $1.0M funded Jan 23, 2026.
- Interest 10% annual on initial note, rising to 12% if second tranche is taken; accrued interest paid only in warrants at maturity.
- Principal repaid in 8 equal quarterly installments from Mar 31, 2027 to Dec 31, 2028; early prepayment fee 1.5-2.75% of principal paid in warrants.
- Lenders include director/10% owner Scott Pittman ($200K) and >5% owner Paul Jacobs ($300K); each received initial and potential second warrants.
- Warrants exercisable at $1.50/share, expiring Jan 23, 2031; up to 226,000 interest warrant shares issuable at maximum borrowing.

## SEC filing metadata
- accession: 0001437749-26-002078
- form_type: 8-K
- ticker: AURX
- cik: 0001091596
- company_name: Nuo Therapeutics, Inc.
- filed_at: 2026-01-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/0001437749-26-002078-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/aurx20260122_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-002078
- JSON: https://secwatch.observer/filing/0001437749-26-002078.json
- Plain text: https://secwatch.observer/filing/0001437749-26-002078.txt

## Key facts
- Debt Financings
  Nuo Therapeutics, Inc. incurred credit facility of aggregate principal amount of up to $1.6 million with four lenders (including Scott M. Pittman and Paul Anthony Jacobs) at annual rate of 10% maturing December 31, 2028.
  - Instrument: credit facility
  - Principal: aggregate principal amount of up to $1.6 million
  - Counterparty: four lenders (including Scott M. Pittman and Paul Anthony Jacobs)
  - Rate: annual rate of 10%
  - Maturity: December 31, 2028
  - Event: incurrence
  source text: On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million with (a) $1.0 million funded on the initial closing date (the “Initial Funding”) and (b) $600 thousand to be funded, if requested in advance by the Company and subject to closing conditions, on September 30, 2026 (the “Second Funding”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/0001437749-26-002078-index.htm
- Material Agreements
  Nuo Therapeutics, Inc. entered into Loan and Security Agreement with four lenders (collectively, the "Lenders") valued at up to $1.6 million (effective 2026-01-21).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: four lenders (collectively, the "Lenders")
  - Value: up to $1.6 million
  - Effective: 2026-01-21
  source text: On January 21, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Loan and Security Agreement (the “Loan Agreement”) with four lenders (collectively, the “Lenders”). The Loan Agreement provides for loans in an aggregate principal amount of up to $1.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1091596/000143774926002078/0001437749-26-002078-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.